Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.

Saved in:
Bibliographic Details
Title: Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.
Authors: Wang JH; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD., Sherry AD; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Bazyar S; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD., Sutera P; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY., Radwan N; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD., Phillips RM; Department of Radiation Oncology, Mayo Clinic, Rochester, MN., Deek MP; Department of Radiation Oncology, Rutgers Cancer Institute, New Brunswick, NJ., Lu J; Department of Oncology, Division of Quantitative Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD., Dipasquale S; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD., Deville C; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD., DeWeese TL; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD., Song DY; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD., Wang H; Department of Oncology, Division of Quantitative Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD., Hobbs RF; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD., Malek R; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD., Dudley SA; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD., Greco SC; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD., Antonarakis ES; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Current address Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Marshall CH; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Current address Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Denmeade S; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Current address Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Paller CJ; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Current address Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Carducci MA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Current address Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Pienta KJ; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Current address Masonic Cancer Center, University of Minnesota, Minneapolis, MN.; Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD., Oz OK; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL., Ramotar M; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX., Leenstra JL; Department of Radiation Oncology, Mayo Clinic, Rochester, MN., Park SS; Department of Radiation Oncology, Mayo Clinic, Rochester, MN., Abramowitz MC; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada., Desai N; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL., Berlin A; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX., Stish BJ; Department of Radiation Oncology, Mayo Clinic, Rochester, MN., Tang C; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Tran PT; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD., Kiess AP; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Jun 20; Vol. 43 (18), pp. 2059-2068. Date of Electronic Publication: 2025 May 07.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; Comparative Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO-25-00131